Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed non-Hodgkin's lymphoma (NHL)
• * Recurrent disease
• * Isolated CNS relapse of systemic NHL allowed
• * Primary CNS lymphoma
• Measurable gadolinium-enhancing lesion on MRI of the brain
• No impaired bone marrow reserve
• No hypocellular bone marrow
• No marked reduction in bone marrow precursors of one or more cell lines (granulocytic, megakaryocytic, erythroid)
• No pleural effusion
• No chronic lymphocytic leukemia
• No AIDS-related lymphoma
• PATIENT CHARACTERISTICS:
• Age
• Adult
• Performance status
• Not specified
• Life expectancy
• Not specified
• Hematopoietic
• Platelet count \> 100,000/mm\^3
• Absolute neutrophil count ≥ 1,500/mm\^3
• Hepatic
• Bilirubin ≤ 2.0 mg/dL
• Renal
• Creatinine ≤ 2.0 mg/dL
• Other
• HIV negative
• No serious nonmalignant disease that would preclude study participation
• No infection
• No anti-murine antibody reactivity\*
• No human anti-mouse antibodies
• Not pregnant
• Negative pregnancy test NOTE: \*Results must be available prior to study entry for patients who received prior murine antibodies or proteins, other than rituximab
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Radiotherapy
• No prior stem cell transplantation
• No prior myeloablative therapies with autologous bone marrow transplantation or peripheral blood stem cell rescue
• No prior failed stem cell collection
• More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• Chemotherapy
• No more than 1 prior chemotherapy regimen
• Endocrine therapy
• Not specified
• Radiotherapy
• No prior radioimmunotherapy
• No prior whole-brain radiotherapy
• No prior external beam radiotherapy (involved field or regional) to \> 25% of active bone marrow
• Surgery
• More than 4 weeks since prior major surgery except diagnostic surgery